27-Jun-2020 | Market Research Store
Scientists have found by studying on the mice that they can turn off a gene that is the possible cause to form breast cancer. They have claimed that by silencing the gene the tumor shrinks and also helps in preventing the spread of the cancerous cells around the body.
The American Cancer Society has reported that in the United States approximately one in eight of the women have chances to develop breast cancer.
As per records, in the year 2019, there were around 268,600 new cases recorded for invasive breast cancer in the U.S. and about 41,760 people died owing to this disease.
Of about a fifth of the breast cancers are aggressive, which is termed as triple-negative breast cancer and it is complex to treat.
In contrast with other major cases of breast cancer it is not progesterone or estrogen that triggers the growth of the triple-negative breast cancer. Thus, drugs such as tamoxifen that block these hormones prove ineffective.
According to a study done at Tulane University School of Medicine in New Orleans, a molecule that turns off a specific gene in the triple-negative tumors have a possibility to be a promising optional treatment. This research study Scientific Reports has been published in the Nature journal.
The research combined in vitro studies of cells growing in dishes with in vivo studies involving mice.
Rab27a and TRAF3IP2 are the two breast cancer genes and the researchers studied the effects by switching them off.
A detailed study was done by the researchers and they came up with the conclusions that switching off TRAF3IP2 was much effective than switching off Rab27a.
Dr. Reza Izadpanah made the statement, “This exciting discovery has revealed that TRAF3IP2 can play a role as a novel therapeutic target in breast cancer treatment.”
Market Research Store has published a report on the breast cancer therapeutics drugs market showcasing the market demand anticipates to increase during the forecast period owing to increasing cases of breast cancer among the individuals.